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Objective 
To examine the use of a clinical pathway in the management of infants hospitalized 
with acute viral bronchiolitis. 
 
Study design 
A clinical pathway with specific management and discharge criteria for the care of 
infants with bronchiolitis was developed from pathways used in tertiary care pediatric 
institutions in Australia. Two hundred and twenty-nine infants admitted to hospital 
with acute viral bronchiolitis and prospectively managed using a pathway protocol 
were compared with a retrospective analysis of 207 infants managed without a 
pathway in 3 regional and 1 tertiary care hospital. 
 
Results 
Readmission to hospital was significantly lower in the pathway group (P = .001), as 
was administration of supplemental fluids (P = .001) and use of steroids (P = .005). 
There were no differences between groups in demographic factors or clinical severity. 
The pathway had no overall effect on length of stay or time in oxygen. 
 
Conclusions 
A clinical pathway specifying local practice guidelines and discharge criteria can 
reduce the risk of readmission to hospital, the use of inappropriate therapies, and help 
with discharge planning.  
 
Abbreviations: ICU, Intensive care unit; LOS, Length of stay; RSV, Respiratory 
syncytial virus; TIO, Time spent in oxygen  
  
 
Clinical pathways, developed to provide a systematic and organized method of 
managing the care of patients with a variety of conditions, have been used 
extensively, often without formal evaluation of their effectiveness.1 and 2 
 
Acute viral bronchiolitis results in hospital admission in about 1 in 100 usually 
healthy infants.3 Clinical pathways for bronchiolitis have been established in pediatric 
tertiary care centers in Australia. Two studies were unable to demonstrate any 
improvement in the management of oxygen therapy or hydration therapy after the 
introduction of clinical pathways; however, they did find a reduction in the use of 
antibiotics.4 and 5 Clinical practice guidelines for bronchiolitis have also been 
assessed and, according to Perlstein et al,6 use of guidelines has produced dramatic 
decreases in the number of admissions and the mean length of stay (LOS). Subsequent 
authors3 have not been able to identify a similar level of success, although one recent 
large study7 found a significant decrease in resource use after introduction of clinical 
guidelines. A recent review of current management provides specific assessment and 
admission guidelines to promote best practice.8 
 
A clinical pathway was developed and used to promote consistency of nursing 
management during a prospective clinical trial of epinephrine at 1 tertiary care and 3 
regional hospitals in southeast Queensland.9 The epinephrine study identified oxygen 
saturation on admission, need for supplemental oxygen, and need for intravenous 
therapy as the major factors affecting LOS in hospital. The intervention of the 
epinephrine study had no effect on outcomes, and there was no difference in outcomes 
between the patients who took part in the study and those patients managed on a 
clinical pathway who did not take part. This lack of difference in outcomes afforded a 
unique opportunity to examine the use of the clinical pathway in the management of 
infants with acute viral bronchiolitis. 
 
Methods 
Selection of Patients 
This study combined a prospective analysis of 229 patients admitted with 
bronchiolitis treated using a pathway protocol (pathway group) with a retrospective 
analysis of 207 randomly selected historical control patients managed without a 
pathway. For inclusion in the study, the infants had to be under 12 months of age (or 
12 months corrected age if premature) with their first wheezing episode requiring 
admission. Infants with heart disease or significant respiratory problems, such as 
cystic fibrosis, and infants who had received corticosteroids within 24 hours of 
presentation or used bronchodilators within the previous 4 hours, were excluded. The 
pathway included specific admission assessment information, clinical management 
guidelines, and discharge criteria (Table I).  
 
 Table I.  
 
Clinical pathway admission assessment, clinical management and discharge criteria 
Initial respiratory assessment recorded  
 Oxygen saturation in room air  
 Respiratory rate and effort  
 Heart rate  
 Temperature  
 Skin color and tone  
 Presence/absence of wheezing and crackles on chest auscultation  
 Level of hydration  
Medical and social history recorded  
 Birth history  
 Birth weight  
 Previous medical problems  
 Infectious disease screening  
 Immunization status  
 Current medications  
 Development assessment  
 Allergies  
 Family history, eg, atopy  
 Social history, esp. smoking status of parents  
 Discharge support eg. LMO/GP  
Guidelines for oxygen administration and supplemental fluids  
 Administer supplemental oxygen if:  
  Oxygen saturation < 94%  
  A combination of: significant respiratory distress, respiratory rate > 60/min, 
difficulty feeding  
 Wean or cease supplemental oxygen if:  
  Oxygen saturation consistently above 93%  
  Infant stable for more than 4 hours and tolerating oral feeds  
 Intravenous fluids administered if:  
  Oxygen required  
  Respiratory rate > 60/min  
  Oral feeding inadequate  
 Intravenous fluids ceased if:  
  Infant able to tolerate oral feeds  
Discharge guidelines  
 Respiratory status stable in room air for > 10 hours  
 Nil or mild chest recessions  
 Oxygen saturation in room air > 93%  
 Discharge plan for the parents complete  
 Letter for the GP complete  
 
 
 
 
Setting and Time Frame 
The setting for this study was 1 tertiary care hospital (Royal Children's Hospital, 
Brisbane) and 3 regional hospitals (Gold Coast Hospital, Redcliffe Hospital, and 
Caboolture Hospital), all located in southeast Queensland. 
 
The historical control group was admitted between May 1998 and August 1999, and 
the infants in the prospective study who were managed on a pathway were admitted 
between May 2000 and August 2001. 
 
Data Collection 
Baseline clinical data, and data on parental smoking, admission to the pediatric 
intensive care unit (ICU), and use of drug therapy were collected from the clinical 
notes for the historical control group and from the clinical pathway records in the 
pathway group. Data on all pathology tests ordered and chest X-ray films were 
obtained from the hospital databases and clinical records. 
 
For the pathway group, infants who required supplemental oxygen, had weaned to air, 
and then required further supplemental oxygen, were identified. The lack of detailed 
documentation about supplemental oxygen requirements in the control group 
prohibited further investigation of these infants. The possible predictive factors that 
could account for this repeated oxygen requirement were examined and included 
hospital site, age, sex, respiratory syncytial virus (RSV) status, severity at admission 
(as determined by oxygen saturation, respiratory rate, and presence of recession), 
length of time of initial supplemental oxygen requirement, need for supplemental 
fluids, and smoking status of parents. 
 
Outcome Measures 
Study outcomes included LOS, time spent in oxygen (TIO), use of supplemental 
fluids, readmission to hospital within 2 weeks of discharge, use of pathology, 
radiological investigations, and medications—specifically antibiotics and steroids—
and predictors for return to oxygen therapy. 
 
Ethics 
Local institutional ethics committees from the 4 centers approved the study. 
 
Sample Size Estimate 
On the basis of a mean LOS of 82 hours and standard deviation of 67 hours from the 
epinephrine study, it was estimated that a sample size of 200 subjects in each group 
was required to detect a difference of 12 hours in length of stay (a clinically relevant 
difference) between groups with a power of 80% and an α = 5%. 
 
Statistical Analysis 
We compared the infants in the historical control group and the infants managed using 
a clinical pathway with respect to demographic data, baseline clinical measures, and 
study outcomes. Comparisons between different hospitals, as well as between the 2 
groups, were made to determine whether there was any interhospital variation in 
practice. The χ2 test for significance was used to determine any statistically 
significant differences between the 2 sets of discrete data, and a 1-way analysis of 
variance test was used for the continuous data. A P value < .05 was considered 
statistically significant. Logistic regression was used to screen risk factors for return 
to oxygen. 
 
Results 
Baseline Demographic and Clinical Data 
The baseline characteristics of the prospective and control groups were similar with 
regard to age, sex, RSV infection, and admitting hospital. The 2 groups had similar 
severity of illness at admission, as determined by presence/absence of recession, 
respiratory rate, requirement for supplemental oxygen, oxygen saturations at 
admission, and admission to ICU (Table II).  
 
 Table II.  
 
Demographic/clinical data at admission (Given as mean [SD])  Control patients (n = 
207) Pathway patients (n = 229) P value  
Age (months) 4.0 ± 3.0 4.3 ± 2.9 .40  
Sex (male/female) 132 (63.8%)/75 (36.2%) 141 (61.6%)/88 (38.4%) .64  
Nasopharyngeal aspirate positive 139 (72.4%) 175 (76.4%) .35  
RSV + 127 (66.1%) 155 (67.7%) .74  
Admission numbers (% of total)   .72  
 RCH 114 (55.1%) 114 (49.8%)   
 GCH 40 (19.3%) 50 (21.8%)   
 Caboolture 27 (13.0%) 31 (13.5%)   
 Redcliffe 26 (12.6%) 34 (14.8%)   
Chest recession present (n) 172 (90.5%) 211 (92.1%) .56  
Respiratory rate (per min) 50.7 (±12.0) 51.8 (±13.6) .41  
O2 saturations on arrival (before oxygen) 93.1% (± 5.3) 93.4% (±4.0) .48  
Supplemental O2 requirement 120 (58.0%) 148 (64.6%) .15  
Admission to ICU 8 (3.9%) 7 (3.1%) .64  
 
 
RCH, Royal Children's Hospital; GCH, Gold Coast Hospital. 
 
 
 
 
Outcome Measures 
There was no significant difference overall between the 2 groups for LOS or TIO. The 
mean LOS in hours for infants in the control group was 86 hours (75.3-96.6, 95% CI), 
and 88.6 hours (78.8-98.3, 95% CI) for the pathway group. The length of stay was 
22.0 hours longer in the tertiary care hospital than in the regional hospitals (P = .006), 
but this difference was reduced to 11.1 hours (P = .064) after adjustment for use of 
supplemental oxygen and supplemental fluids. Fifty-eight percent of infants in the 
control group required supplemental oxygen for a mean time of 72.6 hours (59.9-85.4, 
95% CI), whereas 65% of the pathway group required supplemental oxygen for a 
mean time of 79.9 hours (69.1-90.8, 95% CI). There was a significant difference, 
however, in a subgroup of both cohorts. Infants in the pathway group requiring 
oxygen but not supplemental fluids had a longer LOS (P = .006) and a longer TIO (P 
= .003) than infants in the control group requiring oxygen only. 
 
Fifteen infants (7.2%) in the control group required readmission within 2 weeks after 
discharge, with 9 of these infants also being administered supplemental oxygen during 
their initial hospital stay. This number compares with only 2 infants (0.9%) in the 
pathway group (P = .001) requiring readmission. Both these infants needed 
supplemental oxygen. 
 
Supplemental fluids were administered to 33.8% of the control group compared with 
19.2% of infants managed on a pathway (P = .001); however, more patients required 
supplemental fluids in the tertiary care hospital than regional hospitals (28.9% vs 
16.3%, P = .006) There was greater use of steroids in the control group compared 
with the pathway group (P = .005), although the use of antibiotics was not 
significantly different between the 2 groups. 
 
There was a marked difference between the 2 groups in the collection of data on the 
smoking status of the parents. In the control group, the parental smoking status of 
only 16% of the infants was collected. In the pathway group, however, data on 
smoking status were obtained for every infant (Table III).  
 
 Table III.  
 
Outcome measures (mean - 95% confidence interval) Outcome measures Control 
patients (n = 207) Pathway patients (n = 229) P value  
LOS (hours) 86.0 (75.3-96.6) 88. 6 (78.8-98.3) .72  
 Nil O2 or supp fluids 40.2 (33.1-47.3) 34.4 (29.9-38.9) .18  
 O2 only 81.5 (70.5-92.6) 107.0 (94.9-119.1) .006  
 O2 and supp fluids 158.0 (132.5-183.5) 147.6 (115.7-179.4) .61  
TIO (hours) 72.6 (59.9-85.4) 79.9 (69.1-90.8) .39  
 O2 only 45.0 (35.0-55.1) 69.8 (58.7-80.9) .003  
 O2 and supp fluids 101.1 (79.2-123.1) 106.4 (80.7-132.1) .77  
Number requiring supplemental O2 (%) 120 (58%) 148 (64.6%) .15  
Number requiring supplemental fluids (%) 70 (33.8%) 44 (19.2%) .001  
Readmission within 2 weeks 15 (7.2%) 2 (0.9%) .001  
Parental smoking status known (%) 33 (16%) 229 (100%) .029  
 
 
 
 
There was no significant difference between the 2 groups for the number of chest X-
ray films or pathology tests including blood cultures, arterial blood gases, full blood 
counts, urea and electrolytes and liver function tests, lumbar punctures, methicillin-
resistant Staphylococcus aureus screening, and urine culture and sensitivity tests. A 
higher proportion of patients in the control group (4%) had blood taken for Bordetella 
pertussis compared with the pathway group (0.9%) (χ2 = 6.32; P = .13). In contrast, a 
higher proportion of patients on the pathway (11%) had feces culture and sensitivity 
testing done, compared with the control group (4%) (χ2 = 7.23; P = .007). 
 
Forty infants (27%) on the clinical pathway required supplemental oxygen again after 
being weaned to room air. Boys were 3 times more likely to return to oxygen (OR = 
3.30; 95% CI, 1.39-7.81) after adjusting for oxygen saturations on admission, in spite 
of the fact that there was no significant difference between the oxygen saturation 
levels on admission of boys and girls for the entire cohort. Eight hours of monitoring 
after weaning from oxygen resulted in only 14 (9.5%) requiring a return to oxygen 
therapy. For every 1% increase in admission oxygen saturation levels, the infant's 
likelihood of returning to oxygen decreased by 16% (OR = 0.84; 95% CI, 0.75-0.95). 
Of the infants who did require further supplemental oxygen, 80% had supplemental 
oxygen restarted between 6 am and 6 pm. Time to return to oxygen was not affected 
by sex, age at admission, or oxygen saturation levels on admission. 
 
Discussion 
One of the major benefits of using this clinical pathway for infants with bronchiolitis 
appears to be in discharge planning and reducing the chances of a required 
readmission through the achievement of specified clinical outcomes before discharge. 
This benefit aligns with current findings by Meuthing et al7 that emphasize the 
importance of having specific guidelines, including admission and discharge criteria, 
which direct clinical practice. 
 
Another advantage to be gained from use of a clinical pathway may be a more 
accurate assessment of the infant in relation to their need for supplemental fluids. 
Predetermined guidelines to direct clinical practice may lead to the elimination of 
some variability in practice and the avoidance of unnecessary invasive procedures for 
the patient. It may also be valuable as a cost-cutting measure, both in the up-front 
costs associated with nasogastric and intravenous feeds, and in terms of a reduction in 
the nursing time required in setting up and monitoring these procedures. 
 
The areas in which specific recommendations were identified in the clinical pathway 
were the areas where there were statistically significant differences in outcomes 
between groups. This finding is evidenced by the reduction in the administration of 
supplemental fluids and steroids and the consistent collection of data on parental 
smoking status. The reduction in the use of steroid therapy that we found occurred 
while the patient LOS was unaltered and readmission rates to hospital dropped 
suggests that the change in drug prescribing practice had no detectable negative effect 
on short-term patient outcomes. Wang et al10 describe the variations in interventions 
relating to both steroids and antibiotics, suggesting that variation can occur when the 
most appropriate management is not clear. Areas of the pathway that did not mention 
specific management guidelines such as the administration of antibiotics, and the 
requirements for pathology testing and chest X-ray films, saw no significant change in 
practice between the 2 groups. 
 
The lack of significant difference between the groups overall in terms of LOS or TIO 
suggests that either the particular clinical pathway used was not able to affect these 
outcomes, or that use of any clinical pathway may not significantly change these 
outcome measures for bronchiolitis. The longer LOS for children in the pathway 
group who required supplemental oxygen is likely to be due to the guidelines given 
for oxygen administration. The pathway was designed to be reasonable and acceptable 
to health care providers at a number of centers, and the actual cutoff for an acceptable 
level of oxygen saturation for weaning had not previously been examined. The value 
chosen is likely to have an effect on both LOS and possible readmission and should 
be formally tested. The subgroups of infants from the tertiary care hospital who were 
hospitalized and in supplemental oxygen for longer periods of time would be expected 
because this was the center to which the sicker infants were transferred because it was 
the only one with a pediatric ICU. Boys and infants with lower oxygen saturation 
levels on admission were the most “at-risk” group for requiring further supplemental 
oxygen after being previously weaned to room air. In addition, the fact that 
significantly more infants returned to oxygen therapy during the day may lead us back 
to the cornerstone of bronchiolitis management, namely minimal handling and 
supportive nursing care. 
 
Although the use of a historical control group is not ideal, prospectively randomizing 
patients to pathway care or not pathway care would be extremely difficult from the 
point of view of nursing practice and adherence with pathway use. This study was 
conducted in a variety of hospital settings that allowed larger numbers and also 
ensured that the study participants were likely to be representative of most infants 
hospitalized in either tertiary care or regional hospitals. Seasonal variation occurs with 
bronchiolitis leading to significantly greater numbers presenting during the winter 
months. Genotype variations in the causative organisms for bronchiolitis can mean 
that 1 year might have milder cases than a subsequent year, theoretically resulting in 
shorter LOS or reduced TIO. By collecting data over 2 winter periods, the possibility 
of such an occurrence was minimized. In addition, severity data suggested similar 
groups were studied. 
 
Clinical pathways provide a systematic way of managing the care of infants with 
acute viral bronchiolitis. This pathway significantly decreased the likelihood of 
readmission almost certainly because it provided specific discharge criteria. Other 
tangible positive outcomes from using this pathway with specified management 
criteria were decreased use of supplemental intravenous fluids and steroid therapy and 
the collection of more accurate baseline data. Although this clinical pathway is no 
longer used in the tertiary hospital, it is still being used in the 3 regional centers 
probably because the specific criteria developed at the local level provided guidelines 
in hospitals that do not have large numbers of experienced pediatric staff. This study 
demonstrates the importance of clear specific guidelines to effect change in clinical 
practice. The challenge is to ensure that these guidelines are evidence based and 
achieve the best possible outcomes for patients.  
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